閉塞性心不全の患者における心房内ナトリウレチンペプチドと脳内ナトリウレチンペプチドの異なる分泌パターン
M Yoshimura1, H Yasue, K Okumura
1Division of Cardiology, Kumamoto University School of Medicine, Japan.
Circulation
|February 1, 1993
まとめ
心房内ナトリウレチンペプチド (ANP) と脳内ナトリウレチンペプチド (BNP) の血濃度は,心不全の種類によって異なります. BNPレベルは主に心室過負荷を示しますが,ANPとBNPの分泌パターンは特定の心疾患によって異なります.
科学分野:
- 心臓病学 心臓病学
- バイオケミストリー バイオケミストリー
- 生理学 生理学とは
背景:
- 胸前ナトリウレチンペプチド (ANP) と脳ナトリウレチンペプチド (BNP) のプラズマ濃度は,結血性心不全 (CHF) の重症度と相関しています.
- ANPとBNPの分泌の変動を理解することは,CHFの管理に不可欠です.
研究 の 目的:
- ANPとBNPの分泌パターンが,基礎となる心臓疾患に基づいて,CHFの患者で異なっているかどうかを調査する.
- 異なるCHF病因におけるナトリウレチンペプチドレベルと心房および心室過負荷の程度との関係を評価する.
主な方法:
- 心臓キャセテリゼーションは,ミトラル狭窄症 (MS) の患者20人,拡張性心筋病 (DCM) の患者30人,対照患者20人に実施されました.
- ANPとBNPの血濃度は,大動脈で測定されました.
- 肺毛細血管の圧 (PCWP) と左心室の末期ダイアストリック圧 (LVEDP) を記録した.
主要な成果:
- MSとDCMの両グループは,対照群と比較して,PCWPが著しく上昇したことを示しました.
- 左心室末端ダイアストリック圧力 (LVEDP) は,MSよりもDCMにおいて有意に高かった.
- 血のANPレベルは,MSとDCMの両グループで,対照群と比較して上昇しており,MSとDCMの間には有意な差異はありませんでした.
- 血のBNP濃度は,DCMではMSよりも著しく高く,MSでは対照群よりも高かった.
- DCMでは,ANPとBNPの両方がPCWPと正に相関していました.
- MSでは,ANPはPCWPと相関していたが,BNPはそうではなかった.
結論:
- 血BNPレベルは,CHFにおける心室過負荷の重要な指標である.
- ANPとBNPの分泌パターンは,特定の心疾患と心筋梗塞における心房および心室過負荷の程度によって影響を受けます.
関連する概念動画
Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...


